- Home
- CRL
CRL
Charles River Laboratories International Inc.
as 07-26-2024 4:00pm EST
| Founded: | N/A | Country: | United States |
| Employees: | N/A | City: | WILMINGTON |
| Market Cap: | N/A | IPO Year: | 2000 |
| Target Price: | $252.67 | AVG Volume (30 days): | 473.7K |
| Analyst Decision: | Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 8.52 | EPS Growth: | -11.89 |
| 52 Week Low/High: | $161.65 - $275.00 | Next Earning Date: | 08-07-2024 |
| Revenue: | $4,111,596,000 | Revenue Growth: | 0.49% |
| Revenue Growth (this year): | 3.21% | Revenue Growth (next year): | 7.63% |
Stock Insider Trading Activity of Charles River Laboratories International Inc. (CRL)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| MASSARO GEORGE | CRL | Director | May 15 '24 | Sell | $236.78 | 96 | $22,730.88 | 5,855 | SEC Form 4 |
| MASSARO GEORGE | CRL | Director | May 15 '24 | Sell | $235.61 | 113 | $26,623.93 | 5,951 | SEC Form 4 |
| MASSARO GEORGE | CRL | Director | May 15 '24 | Sell | $234.72 | 123 | $28,870.56 | 6,064 | SEC Form 4 |
| LaPlume Joseph W | CRL | EVP, Corp Strategy & Develop | May 10 '24 | Sell | $226.97 | 1,304 | $295,968.88 | 23,276 | SEC Form 4 |
| Knell Michael Gunnar | CRL | CSVP&Chief Accounting Officer | Mar 8 '24 | Sell | $267.52 | 808 | $216,156.16 | 7,825 | SEC Form 4 |
| Knell Michael Gunnar | CRL | CSVP&Chief Accounting Officer | Mar 8 '24 | Sell | $267.52 | 808 | $216,156.16 | 7,024 | SEC Form 4 |
| Knell Michael Gunnar | CRL | CSVP&Chief Accounting Officer | Mar 4 '24 | Sell | $260.88 | 1,750 | $456,540.00 | 8,832 | SEC Form 4 |
| Knell Michael Gunnar | CRL | CSVP&Chief Accounting Officer | Mar 4 '24 | Sell | $261.35 | 1,000 | $261,350.00 | 7,832 | SEC Form 4 |
| Creamer Victoria L | CRL | EVP & Chief People Officer | Feb 29 '24 | Sell | $253.70 | 5,000 | $1,268,500.00 | 13,550 | SEC Form 4 |
| Parisotto Shannon M | CRL | CEVP, Disc & Safety Assessment | Feb 29 '24 | Sell | $253.43 | 3,686 | $934,142.98 | 4,792 | SEC Form 4 |
| Parisotto Shannon M | CRL | CEVP, Disc & Safety Assessment | Feb 29 '24 | Sell | $254.02 | 100 | $25,402.00 | 7,132 | SEC Form 4 |
| Barbo William D | CRL | Corporate Executive VP & CCO | Feb 22 '24 | Sell | $248.50 | 4,050 | $1,006,425.00 | 22,879 | SEC Form 4 |
| LaPlume Joseph W | CRL | EVP, Corp Strategy & Develop | Feb 15 '24 | Sell | $238.93 | 838 | $200,223.34 | 24,620 | SEC Form 4 |
| Parisotto Shannon M | CRL | CEVP, Disc & Safety Assessment | Feb 15 '24 | Sell | $237.20 | 291 | $69,025.20 | 8,187 | SEC Form 4 |
| Parisotto Shannon M | CRL | CEVP, Disc & Safety Assessment | Feb 15 '24 | Sell | $239.28 | 1,290 | $308,671.20 | 6,897 | SEC Form 4 |
| Parisotto Shannon M | CRL | CEVP, Disc & Safety Assessment | Feb 15 '24 | Sell | $240.12 | 1,617 | $388,274.04 | 5,280 | SEC Form 4 |
| Parisotto Shannon M | CRL | CEVP, Disc & Safety Assessment | Feb 15 '24 | Sell | $241.28 | 610 | $147,180.80 | 4,670 | SEC Form 4 |
| Parisotto Shannon M | CRL | CEVP, Disc & Safety Assessment | Feb 15 '24 | Sell | $242.43 | 632 | $153,215.76 | 4,038 | SEC Form 4 |
| Parisotto Shannon M | CRL | CEVP, Disc & Safety Assessment | Feb 15 '24 | Sell | $243.96 | 604 | $147,351.84 | 3,434 | SEC Form 4 |
| Parisotto Shannon M | CRL | CEVP, Disc & Safety Assessment | Feb 15 '24 | Sell | $244.61 | 749 | $183,212.89 | 2,685 | SEC Form 4 |
| Parisotto Shannon M | CRL | CEVP, Disc & Safety Assessment | Feb 15 '24 | Sell | $245.34 | 89 | $21,835.26 | 2,596 | SEC Form 4 |
| Creamer Victoria L | CRL | EVP & Chief People Officer | Dec 14 '23 | Sell | $225.00 | 5,526 | $1,243,350.00 | 16,506 | SEC Form 4 |
| LaPlume Joseph W | CRL | EVP, Corp Strategy & Develop | Nov 30 '23 | Sell | $197.73 | 1,850 | $365,800.50 | 23,133 | SEC Form 4 |
| Girshick Birgit | CRL | Corporate Executive VP & COO | Mar 1 '21 | Buy | $187.82 | 1,322 | $248,298.04 | 44,449 | SEC Form 4 |
Latest Charles River Laboratories International Inc. News
CRL Breaking Stock News: Dive into CRL Ticker-Specific Updates for Smart Investing
MT Newswires
2 days ago
Charles River Laboratories Invests in Autobahn Labs Under Collaborative Deal
Zacks
2 days ago
Here's How Charles River (CRL) is Placed Ahead of Q2 Earnings
Business Wire
2 days ago
Charles River Laboratories and Autobahn Labs Announce Collaborative Program to Accelerate Academic Drug Discovery
Business Wire
10 days ago
Charles River Laboratories Schedules Second-Quarter 2024 Earnings Release and Conference Call
MT Newswires
10 days ago
Stephens Adjusts Price Target on Charles River Laboratories International to $250 From $280
Simply Wall St.
15 days ago
Those who invested in Charles River Laboratories International (NYSE:CRL) five years ago are up 50%
MT Newswires
16 days ago
Baird Adjusts Price Target on Charles River Laboratories International to $239 From $271
Zacks
17 days ago
Charles River (CRL) Teams Up to Aid Stargardt's Disease Therapy
Compare CRL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "CRL Charles River Laboratories International Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.